Home / Solutions
Our solutions
Leveraging precision-cut tissue slices (PCTS), we help drug developers generate human-relevant evidence, increasing preclinical decision confidence and reducing translational uncertainty.
Don’t approximate human biology, test it
Surrogate models fail to produce reliable data. In-vitro cell cultures and organoids fail to recreate tissue complexity and therapeutic responses in animal models are rarely replicated in the clinic.
Human tissue provides a more translatable platform to understand therapeutic response in real human disease.
FibroFind’s PCTS platform bridges the gap by enabling studies in viable, intact human tissue, supporting translational confidence, portfolio prioritisation and earlier go or no-go decisions.
Make your next decision with confidence
Find out how we replace biological guesswork with clarity, giving high-potential assets the best chance to reach patients.
The new standard
Combining the benefits of ex-vivo PCTS and our proprietary bioreactor technology, our platform generates credible, human-relevant evidence to de-risk your drug discovery and development to support stronger preclinical decisions.
Because attrition costs
With fewer than 10% of drug candidates reaching approval, every preclinical decision carries significant capital and reputational consequences. Advancing the wrong asset on the basis of uncertain data compounds that risk substantially.
Rather than relying on simplified cell culture systems or costly animal models, our bioreactor-supported PCTS platform enables drug response to be studied directly in viable, intact human tissue.
We help underpin your strategy with the defensible, human-relevant evidence required to protect asset valuation, drive capital efficiency and secure project funding.
Related resources
Explore how FibroFind’s solutions help drug developers increase confidence in preclinical decision-making using intact, viable human tissue with disease present.
Poster
Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices
See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.
The evidence your program demands
Speak to our team about your program.